![]() ![]() The shares were bought at an average price of $5.67 per share, for a total transaction of $499,232.16. In related news, Director John Mendlein bought 88,048 shares of the company’s stock in a transaction that occurred on Wednesday, January 11th. now owns 6,737 shares of the biopharmaceutical company’s stock valued at $260,000 after acquiring an additional 986 shares during the last quarter. raised its stake in shares of Fate Therapeutics by 17.1% during the first quarter. Finally, PNC Financial Services Group Inc. Private Advisor Group LLC now owns 9,481 shares of the biopharmaceutical company’s stock valued at $367,000 after acquiring an additional 1,938 shares during the last quarter. ![]() Private Advisor Group LLC raised its stake in shares of Fate Therapeutics by 25.7% during the first quarter. ![]() HighTower Advisors LLC now owns 18,361 shares of the biopharmaceutical company’s stock valued at $714,000 after acquiring an additional 1,016 shares during the last quarter. HighTower Advisors LLC raised its stake in shares of Fate Therapeutics by 5.9% during the first quarter. Raymond James & Associates now owns 29,436 shares of the biopharmaceutical company’s stock valued at $1,141,000 after acquiring an additional 8,790 shares during the last quarter. Raymond James & Associates raised its stake in shares of Fate Therapeutics by 42.6% during the first quarter. now owns 8,734 shares of the biopharmaceutical company’s stock worth $339,000 after purchasing an additional 1,457 shares during the last quarter. lifted its stake in Fate Therapeutics by 20.0% in the first quarter. Several other hedge funds have also added to or reduced their stakes in FATE. Tower Research Capital LLC TRC’s holdings in Fate Therapeutics were worth $1,211,000 at the end of the most recent quarter. The firm owned 54,039 shares of the biopharmaceutical company’s stock after purchasing an additional 46,653 shares during the period. ( NASDAQ:FATE – Get Rating) by 631.6% in the 3rd quarter, reports. Fundamental company data provided by Morningstar, updated daily.Tower Research Capital LLC TRC boosted its holdings in Fate Therapeutics, Inc. Stock quotes provided by InterActive Data. The gurus listed in this website are not affiliated with, LLC. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. Past performance is a poor indicator of future performance. ![]() In no event shall be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on, or relating to the use of, or inability to use, or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Gurus may be added or dropped from the GuruFocus site at any time. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Under no circumstances does any information posted on represent a recommendation to buy or sell a security. This investment adviser does not provide advice to individual investors. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. is not operated by a broker or a dealer. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |